Nurix Shares Fall 34% After Sanofi Ends Drug Development Program
Nurix said Sanofi is terminating a drug development program under the companies’ collaboration agreement. Shares fell 34% to $17.07 in after-hours trading Tuesday.
By Elias SchisgallShares of Nurix Therapeutics plunged after the company said Sanofi was terminating a drug development program under the two companies' collaboration agreement.Shares fell 34% to $17.07 in after-hours trading on Tuesday. The stock closed up 0.5% at $25.82, up 36% this year.Sanofi n…